Comprehensive metabolomic characterization of atrial fibrillation

BackgroundUsing human humoral metabolomic profiling, we can discover the diagnostic biomarkers and pathogenesis of disease. The specific characterization of atrial fibrillation (AF) subtypes with metabolomics may facilitate effective and targeted treatment, especially in early stages.ObjectivesBy in...

Full description

Bibliographic Details
Main Authors: Chengcan Lu, Chunyan Liu, Di Mei, Mengjie Yu, Jian Bai, Xue Bao, Min Wang, Kejia Fu, Xin Yi, Weihong Ge, Jizhong Shen, Yuzhu Peng, Wei Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.911845/full
_version_ 1811314618921910272
author Chengcan Lu
Chengcan Lu
Chengcan Lu
Chunyan Liu
Di Mei
Mengjie Yu
Jian Bai
Xue Bao
Min Wang
Kejia Fu
Xin Yi
Weihong Ge
Jizhong Shen
Yuzhu Peng
Yuzhu Peng
Yuzhu Peng
Wei Xu
author_facet Chengcan Lu
Chengcan Lu
Chengcan Lu
Chunyan Liu
Di Mei
Mengjie Yu
Jian Bai
Xue Bao
Min Wang
Kejia Fu
Xin Yi
Weihong Ge
Jizhong Shen
Yuzhu Peng
Yuzhu Peng
Yuzhu Peng
Wei Xu
author_sort Chengcan Lu
collection DOAJ
description BackgroundUsing human humoral metabolomic profiling, we can discover the diagnostic biomarkers and pathogenesis of disease. The specific characterization of atrial fibrillation (AF) subtypes with metabolomics may facilitate effective and targeted treatment, especially in early stages.ObjectivesBy investigating disturbed metabolic pathways, we could evaluate the diagnostic value of biomarkers based on metabolomics for different types of AF.MethodsA cohort of 363 patients was enrolled and divided into a discovery and validation set. Patients underwent an electrocardiogram (ECG) for suspected AF. Groups were divided as follows: healthy individuals (Control), suspected AF (Sus-AF), first diagnosed AF (Fir-AF), paroxysmal AF (Par-AF), persistent AF (Per-AF), and AF causing a cardiogenic ischemic stroke (Car-AF). Serum metabolomic profiles were determined by gas chromatography–mass spectrometry (GC-MS) and liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). Metabolomic variables were analyzed with clinical information to identify relevant diagnostic biomarkers.ResultsThe metabolic disorders were characterized by 16 cross-comparisons. We focused on comparing all of the types of AF (All-AFs) plus Car-AF vs. Control, All-AFs vs. Car-AF, Par-AF vs. Control, and Par-AF vs. Per-AF. Then, 117 and 94 metabolites were identified by GC/MS and LC-QTOF-MS, respectively. The essential altered metabolic pathways during AF progression included D-glutamine and D-glutamate metabolism, glycerophospholipid metabolism, etc. For differential diagnosis, the area under the curve (AUC) of specific metabolomic biomarkers ranged from 0.8237 to 0.9890 during the discovery phase, and the predictive values in the validation cohort were 78.8–90.2%.ConclusionsSerum metabolomics is a powerful way to identify metabolic disturbances. Differences in small–molecule metabolites may serve as biomarkers for AF onset, progression, and differential diagnosis.
first_indexed 2024-04-13T11:15:43Z
format Article
id doaj.art-8b426a449ae44ddf9061ff699cacf010
institution Directory Open Access Journal
issn 2297-055X
language English
last_indexed 2024-04-13T11:15:43Z
publishDate 2022-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cardiovascular Medicine
spelling doaj.art-8b426a449ae44ddf9061ff699cacf0102022-12-22T02:48:59ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-08-01910.3389/fcvm.2022.911845911845Comprehensive metabolomic characterization of atrial fibrillationChengcan Lu0Chengcan Lu1Chengcan Lu2Chunyan Liu3Di Mei4Mengjie Yu5Jian Bai6Xue Bao7Min Wang8Kejia Fu9Xin Yi10Weihong Ge11Jizhong Shen12Yuzhu Peng13Yuzhu Peng14Yuzhu Peng15Wei Xu16Nanjing Drum Tower Hospital, China Pharmaceutical University, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaDepartment of Cardiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaNanjing Drum Tower Hospital, China Pharmaceutical University, Nanjing, ChinaNanjing Drum Tower Hospital, China Pharmaceutical University, Nanjing, ChinaKey Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, ChinaDepartment of Cardiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaDepartment of Cardiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaNanjing Drum Tower Hospital, China Pharmaceutical University, Nanjing, ChinaKey Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaNanjing Drum Tower Hospital, China Pharmaceutical University, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaDepartment of Cardiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaNanjing Drum Tower Hospital, China Pharmaceutical University, Nanjing, ChinaBackgroundUsing human humoral metabolomic profiling, we can discover the diagnostic biomarkers and pathogenesis of disease. The specific characterization of atrial fibrillation (AF) subtypes with metabolomics may facilitate effective and targeted treatment, especially in early stages.ObjectivesBy investigating disturbed metabolic pathways, we could evaluate the diagnostic value of biomarkers based on metabolomics for different types of AF.MethodsA cohort of 363 patients was enrolled and divided into a discovery and validation set. Patients underwent an electrocardiogram (ECG) for suspected AF. Groups were divided as follows: healthy individuals (Control), suspected AF (Sus-AF), first diagnosed AF (Fir-AF), paroxysmal AF (Par-AF), persistent AF (Per-AF), and AF causing a cardiogenic ischemic stroke (Car-AF). Serum metabolomic profiles were determined by gas chromatography–mass spectrometry (GC-MS) and liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). Metabolomic variables were analyzed with clinical information to identify relevant diagnostic biomarkers.ResultsThe metabolic disorders were characterized by 16 cross-comparisons. We focused on comparing all of the types of AF (All-AFs) plus Car-AF vs. Control, All-AFs vs. Car-AF, Par-AF vs. Control, and Par-AF vs. Per-AF. Then, 117 and 94 metabolites were identified by GC/MS and LC-QTOF-MS, respectively. The essential altered metabolic pathways during AF progression included D-glutamine and D-glutamate metabolism, glycerophospholipid metabolism, etc. For differential diagnosis, the area under the curve (AUC) of specific metabolomic biomarkers ranged from 0.8237 to 0.9890 during the discovery phase, and the predictive values in the validation cohort were 78.8–90.2%.ConclusionsSerum metabolomics is a powerful way to identify metabolic disturbances. Differences in small–molecule metabolites may serve as biomarkers for AF onset, progression, and differential diagnosis.https://www.frontiersin.org/articles/10.3389/fcvm.2022.911845/fullatrial fibrillationmetabolomicsdiagnostic modelrisk factorsbiomarker
spellingShingle Chengcan Lu
Chengcan Lu
Chengcan Lu
Chunyan Liu
Di Mei
Mengjie Yu
Jian Bai
Xue Bao
Min Wang
Kejia Fu
Xin Yi
Weihong Ge
Jizhong Shen
Yuzhu Peng
Yuzhu Peng
Yuzhu Peng
Wei Xu
Comprehensive metabolomic characterization of atrial fibrillation
Frontiers in Cardiovascular Medicine
atrial fibrillation
metabolomics
diagnostic model
risk factors
biomarker
title Comprehensive metabolomic characterization of atrial fibrillation
title_full Comprehensive metabolomic characterization of atrial fibrillation
title_fullStr Comprehensive metabolomic characterization of atrial fibrillation
title_full_unstemmed Comprehensive metabolomic characterization of atrial fibrillation
title_short Comprehensive metabolomic characterization of atrial fibrillation
title_sort comprehensive metabolomic characterization of atrial fibrillation
topic atrial fibrillation
metabolomics
diagnostic model
risk factors
biomarker
url https://www.frontiersin.org/articles/10.3389/fcvm.2022.911845/full
work_keys_str_mv AT chengcanlu comprehensivemetabolomiccharacterizationofatrialfibrillation
AT chengcanlu comprehensivemetabolomiccharacterizationofatrialfibrillation
AT chengcanlu comprehensivemetabolomiccharacterizationofatrialfibrillation
AT chunyanliu comprehensivemetabolomiccharacterizationofatrialfibrillation
AT dimei comprehensivemetabolomiccharacterizationofatrialfibrillation
AT mengjieyu comprehensivemetabolomiccharacterizationofatrialfibrillation
AT jianbai comprehensivemetabolomiccharacterizationofatrialfibrillation
AT xuebao comprehensivemetabolomiccharacterizationofatrialfibrillation
AT minwang comprehensivemetabolomiccharacterizationofatrialfibrillation
AT kejiafu comprehensivemetabolomiccharacterizationofatrialfibrillation
AT xinyi comprehensivemetabolomiccharacterizationofatrialfibrillation
AT weihongge comprehensivemetabolomiccharacterizationofatrialfibrillation
AT jizhongshen comprehensivemetabolomiccharacterizationofatrialfibrillation
AT yuzhupeng comprehensivemetabolomiccharacterizationofatrialfibrillation
AT yuzhupeng comprehensivemetabolomiccharacterizationofatrialfibrillation
AT yuzhupeng comprehensivemetabolomiccharacterizationofatrialfibrillation
AT weixu comprehensivemetabolomiccharacterizationofatrialfibrillation